Psychedelic Interest Booms
Despite global COVID shutdowns and declines in medical research funding not related to the pandemic, interest in psychedelic use to treat addictions and other psychological issues is booming. The rise in popularity is happening in the business sector and beyond. While specific industries suffered economic blows due to COVID, notable psychedelic companies either went public or secured millions in funding. Currently, the U.S. Food and Drug Administration is conducting clinical trials involving psychedelic substances such as ibogaine, ketamine, and …